RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
China has added 148 drugs to its list of medicines covered by basic medical insurance plans, the first update in two years. The additions were comprised of 47 western drugs and 101 TCM products, including medicines for cancers, rare diseases, chronic diseases and children’s diseases, as well as some basic drugs. Still unfinished is an additional list that includes expensive drugs of high clinical value, the new therapies for cancer and other medications. These drugs require price negotiations with drug pharmas over the China cost of the products, particularly for western biopharma companies. Source: China Biotoday